Table 1.
Clinical characteristics of the patients in the study prior to initiation of ozone therapy.
| Patient | Age | LHB | HB | Blood transfusion | Endoscopic treatments | Toxicity score |
|---|---|---|---|---|---|---|
| #1 | 73 | 7.4 | 8 | 5 | 3 | 4 |
| #2 | 74 | 6.6 | 7 | 4 | 5 | 3 |
| #3 | 69 | 5.6 | 7 | 3 | 4 | 3 |
| #4∗ | 67 | 5 | 12 | 0 | 0 | 4 |
| #5 | 66 | 7.3 | 11 | 1 | 0 | 3 |
| #6 | 64 | 12.7 | 14 | 0 | 5 | 3 |
| #7 | 73 | 6.1 | 7 | 2 | 5 | 3 |
| #8 | 70 | 11.6 | 12 | 0 | 0 | 2 |
| #9 | 69 | 6.5 | 8 | 11 | 4 | 4 |
| #10 | 73 | 11.8 | 12 | 0 | 0 | 3 |
| #11 | 68 | NA∗∗ | NA∗∗ | 0 | 10 | 3 |
| #12 | 77 | 14 | 14 | 0 | 1 | 2 |
Note: LHB: lowest hemoglobin value (in g/dL) prior to initiation of ozone therapy.
HB: hemoglobin level in g/dL prior to the initiation of ozone therapy.
∗Patient #4 was a referral for surgery from a different hospital, and details of previous blood transfusion and therapeutic endoscopy were not available.
∗∗NA: patient #11 did not have anemia, but the precise hemoglobin value had not been recorded.
Toxicity grade was according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) grading system (version 4.0): available from http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.